Thermo Fisher to Buy Life Technologies for $13.6 Billion in Bid to Beef Up Its Share of Next-Generation Genetic Testing Market

Multi-billion-dollar mega-deal positions Thermo Fisher to offer a broader spectrum of gene sequencing systems to clinical laboratories and pathology groups Earlier this week, Thermo Fisher Scientific, Inc., (NYSE: TMO) of Waltham, Massachusetts, announced a deal that will shake up the market for next-generation gene sequencing and genetic testing. It will acquire Life Technologies Corporation (NASDAQ: LIFE) of Carlsbad, California. More IVD Industry Consolidation That Affects Clinical...

Quest Diagnostics to Pay $740 Million to Acquire Athena Diagnostics from Thermo Fisher

It’s a strong price to pay for this specialty clinical pathology laboratory company Today, Thermo Fisher Scientific Inc. (NYSE:TMO) announced that it was selling its Athena Diagnostics clinical pathology laboratory business to Quest Diagnostics Incorporated (NYSE:DGX). The purchase price will be $740 million, making this the highest-priced medical laboratory acquisition of 2011. Based in Worcester, Massachusetts, Athena Diagnostics is known for its expertise in diagnostic tests for...

Thermo Fisher Trumped by Merck KGaA’s $7.2 Billion Bid to Acquire Millipore

Clinical Pathology Laboratory Customers of Millipore Not Likely to See Many Changes It only took a few days for Millipore Corporation (NYSE: MIL) to find a buyer willing to outbid Thermo Fisher Scientific Inc. (NYSE: TMO). Millipore agreed to be acquired by Merck KGaA (FWB: MRK) of Darmstadt, Germany. Merck will pay about $7.2 billion for Millipore, which tops a reported bid of $6 billion made by Thermo Fisher last week. Because many clinical pathology laboratories use Millipore’s water...
;